TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05498792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL0137
Description: Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL0137
Description: Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL0137
Description: Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patient will be on Ipilimumab (1 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patient will be on Ipilimumab (1 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patient will be on Ipilimumab (1 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patient will be on Nivolumab (3 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patient will be on Nivolumab (3 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patient will be on Nivolumab (3 mg/kg)
Study: NCT06659354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pregnant Body Project (PBP)
Description: The Body Project is typically delivered as four 1-hour weekly sessions consisting of written, verbal, and behavioral exercises. The sessions aim to induce cognitive dissonance by encouraging participants to challenge the thin-ideal, a theoretically and empirically supported component of ED prevention. This adapted version of the Body Project (the Pregnant Body Project; PBP) consists of 6 1-hour, weekly group sessions delivered via Zoom. Since the target population consists of individuals with histories of an ED or disordered eating behaviors, PBP also includes elements from a treatment intervention (i.e., the Body Project Treatment 8.0 manual). PBP was adapted iteratively with a needs assessment, expert stakeholder input, and participant feedback following a mock trial with individuals with lived experience (i.e., individuals with histories of an ED who have given birth). This condition will be peer-delivered by facilitators with lived experience.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pregnancy Health Education (PHE)
Description: This time- dose- and attention- matched control condition accounts for the potential effects of time spent and support from group members and facilitators. Participants assigned to the PHE group will also be asked to attend 6, 1-hour, weekly group sessions via Zoom. During the sessions participants receive psychoeducation on body image and disordered eating during pregnancy but will not engage in any dissonance-inducing exercises. Participants will also receive lifestyle education specific to pregnancy (e.g., proper nutrition, sleep, physical activity), tied back to body image and disordered eating.
Study: NCT06657820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia in healthy individuals
Description: The subject will undergo a graduated desaturation procedure. Arterial saturation targets are as follows:~1. 100%~2. 99%~3. 96%~4. 93%~5. 90%~6. 87%~7. 84%~8. 81%~9. 78%~10. 75%~11. 72%~12. 69%~13. 99%
Study: NCT05038189

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trunk position sense
Description: Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
Study: NCT04818112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATVV
Description: A 15-minute behavioral intervention that mothers administer once daily to their infant for 3 months providing Auditory, Tactile, Visual, and Vestibular (ATVV) stimulation. Multisensory stimuli are presented in gradual progression. Mother-infant engagement is attempted throughout ATVV so that mothers learn to identify, interpret and adapt to their infants cues. ATVV can be given without eye to eye gaze making it appropriate for newborns. ATVV is offered contingent on infant cues to promote self-regulation and withdrawn if any persistent disengagement cues. Mothers are taught how to adapt ATVV as their infant grows. Fidelity to the intervention is checked with weekly phone calls and monthly study visits. Mothers also receive a daily text from REDCap to document an intervention frequency log.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: Mothers in the Attention Control group receive a similar amount of daily texts, weekly phone call and in-person study visit attention as mothers in the ATVV group, but with distinctly different content. Over the first 3 postnatal months, mothers learn safe infant-care that includes content on diapers, infant clothing, blankets, infant care including bathing, sleep positions, sleep habits, holding the baby, safety of infant equipment, breastfeeding, formula, and age appropriate toys.
Study: NCT05141539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation assessment software
Description: In phase 2, this software will be tested in occupational therapists, and head and neck cancer patients results for reliability and validity.~In phase 3, the experiment in the oropharyngeal dysphagia specialists results in content validity, the comparison between the developed software, and VFSS and FOIS results in criterion-related validity, and the experiment in head and neck cancer patients results in reliability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFSS and FOIS
Description: In phase 3, this study applies VFSS and FOIS for the head and neck cancer patients for comparison with the developed rehabilitation assessment software for criterion-related validity.
Study: NCT06657820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral Oximetry
Description: Each subject will be continuously monitored with the cerebral oximetry device throughout the desaturation procedure.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Gas Sampling
Description: At each arterial saturation plateau venous and arterial blood gas measurements will be taken from the jugular bulb, and the radial artery respectively.
Study: NCT06662318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Fentanyl was given as a bolus of 1 µg/kg injected followed by a fentanyl infusion of 0.4 µg/kg/h. Fentanyl infusion was continued as Postoperative analgesia for 24 hours in a dose of 0.3 µg/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was given as a loading dose of 0.6 µg/kg, which was diluted to a total volume of 10 cc of normal saline and injected before induction of anesthesia over 10 minutes. Then, a DXM infusion prepared to provide 0.2-0.7 µg/kg/h was started Intraoperative; Postoperative DXM infusion was provided in a dose of 0.15 µg/kg/h for 24-h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Lidocaine hydrochloride was provided as 2 mg/kg slowly IV before induction of anesthesia and as an IV infusion at a rate of 3 mg/kg/h. Postoprative lidocaine infusion at a dose of 1.5 mg/kg/h was administered for 24 Postoprative hours.
Study: NCT06657885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi
Description: cabotegravir initiation: daily oral route of 1 tablet 30 mg at Day 0 to week 4 Cabotegravir maintennace: Every 8 weeks (+/- 1 week) intramuscular injection from week 8 at week 48.~Lenacapavir initiation: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites + orale route of 2 tablets of 300mg (ie 600 mg) at Day 0 and at day 1: orale route of 2 tablets of 300mg (ie 600 mg) Lenacapavir maintenance: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites every 24 weeks (+/-1 week) from Day 0 to Week 48
Study: NCT06658509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: High-intensity interval training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIT
Description: Sprint interval training
Study: NCT05332639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool
Description: We will develop a web-based, personalized risk estimation for CD (PRE-Crohn's) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI); smoking history; NSAID use; intake of fruit, fiber, and added sugar; oral contraceptive use (females); antibiotic use; breast-feeding; pets in home; and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Crohn's Disease Education
Description: The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-Crohn's tool as well.
Study: NCT04989309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS will be delivered in 10 Hz pulses for 2.5 seconds, with behavioral measures of speech perception and object categorization immediately following each pulse. TMS at this schedule is thought to temporarily disrupt activity at the stimulation site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS will be delivered in 10 Hz pulses for 2.5 seconds, with behavioral measures of speech perception and object categorization immediately following each pulse. TMS at this schedule is thought to temporarily disrupt activity at the stimulation site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS will be delivered in 10 Hz pulses for 2.5 seconds, with behavioral measures of speech perception and object categorization immediately following each pulse. TMS at this schedule is thought to temporarily disrupt activity at the stimulation site.
Study: NCT06615817

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: In this group, a diet based on intermittent fasting will be administered - with 14 hours of nocturnal fasting and 10 hours of feeding with a low glycemic index Mediterranean diet.
Study: NCT06621732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cutanous biopsy and blood sample
Description: cutanous biopsy and blood sample
Study: NCT05980611

Intervention type: DIAGNOSTIC_TEST
Intervention: IL B,IL 3 in nasal swap and serum
Description: Interleukin (IL)-1-beta and IL-3 will be measured in patients' serum and supernatant from the nasal swap using enzyme linked immunosorbent assay (ELISA).

Intervention type: DIAGNOSTIC_TEST
Intervention: IL B,IL 3 in nasal swap and serum
Description: Interleukin (IL)-1-beta and IL-3 will be measured in patients' serum and supernatant from the nasal swap using enzyme linked immunosorbent assay (ELISA).
Study: NCT04794218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^4 pfu delivered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^5 pfu delivered intramuscularly
Study: NCT04742764

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy
Description: Standard medical therapy (according to the Surviving Sepsis Campaign) will include standard monitoring (pulseoximetry, 5-lead ECG, continuous invasive blood pressure monitoring, central venous cannulation and 24 with PiCCO-technology. Norepinephrine as a vasopressor and dobutamine - if needed - as an inotrope will be administered by the attending physician.
Study: NCT04794218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^5 pfu delivered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^6 pfu delivered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^6 pfu delivered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^7 pfu delivered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^7 pfu delivered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^7 pfu delivered intramuscularly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Diluent
Description: N/A delivered intramuscularly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Diluent
Description: N/A delivered intramuscularly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Diluent
Description: N/A delivered intramuscularly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Diluent
Description: N/A delivered intramuscularly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Diluent
Description: N/A delivered intramuscularly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Diluent
Description: N/A delivered intramuscularly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Diluent
Description: N/A delivered intramuscularly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Diluent
Description: N/A delivered intramuscularly
Study: NCT06021730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized After Visit Instructions Only
Description: The intervention took a standardized approach to after visit instructions which included a customizable template that would review patients conditions, changes in any medications, and any future labs, imaging, or referrals.
Study: NCT06175520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preconception care (PCC)
Description: The investigators will introduce PCC through the existing public health system. At the community level facility, healthcare providers will screen the women for some specific health problems and provide necessary supplements. Healthcare providers will screen for health problems such as- infectious diseases (e.g., Tuberculosis), Hypertension, Anaemia, Diabetes Mellitus, Thyroid problems, Sexually Transmitted Infection/Reproductive Tract Infection/Urinary Tract Infection, Nutritional status (e.g., Body mass index), Thalassemia symptoms, Thyroid symptoms, severe Dysmenorrhea, Immunization status, and Symptoms of acute Hepatitis B Virus infection, etc. The provider will also consider age, menstrual history, and reproductive history during preconception screening. If the provider finds any abnormality from the screening test which is a risk for a woman to become pregnant and for her newborn; the woman will be provided proper counseling, treatment, and referral to the appropriate facility.
Study: NCT06021730

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized After Visit Instructions & Teach Back
Description: This intervention included the Standardized After Visit Instructions and included teach back, a process by which patients restate in their own words their understanding of their condition, what was discussed in the visit, and what potential changes were made
Study: NCT05307419

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal suction biopsy.
Description: Suction biopsy performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal suction biopsy.
Description: Suction biopsy performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-thickness rectal biopsy.
Description: Full-thickness biopsy performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-thickness rectal biopsy.
Description: Full-thickness biopsy performed
Study: NCT04803825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy Slow Exercises
Description: * Load magnitude: A dumbbell as heavy as possible within the given repetitions and sets.~* Number of repetitions: week 1: 15 reps, Week 2-3: 12 reps, Week 4-5: 10 reps, Week 6-8: 8 reps, Week 9-12: 6 reps~* Number of sets: 3~* Rest between sets: 2 - 3 min.~* Number of exercise interventions: 2~* Duration of experimental period: 12 weeks~* Fractional and temporal distribution of the contraction modes per repetition and duration of one repetition: 3s concentric, 2s isometric: while change concentric/eccentric phase, 3s eccentric.~* Rest in-between repetitions: No~* Range of motion: Full range of motion~* Intervention frequency: 3 times a week, with minimum 48 h recovery time in-between.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock wave therapy
Description: Two thousand impulses of shock waves are applied to the painful tendon, with a pressure between 1.5 and 3.0 bar (depending on what the patient tolerates). We use a power hand piece that provides energy of 0.01-0.35 mJ/mm2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information and advice
Description: Information and advice are based on assessment and will comprise the standardized oral and written information. Participants will be educated regarding pain during and after activities and encouraged to be physically active. With only one session, there is great reliance on self-management. Thus, information and advice are made available through a handout.
Study: NCT05931861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2769
Description: T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.
Study: NCT04742764

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours
Description: Standard medical therapy, as discussed above will be applied. Furthermore, Cytosorb will be administered as soon as it is possible after randomization but not later than 2 hour (start of the treatment, T0). In a blood pump circuit in pre-haemofilter position, using a kidney replacement device of Fresenius Multifiltrate as a solo therapy or in combination with renal replacement therapy. It will be run in CVVHD, CVVHDF or CVVH mode with a 150 and 200 ml/min blood flow. Anticoagulation will be applied intravenously with heparin, low molecular weight heparin or citrate. The aim of the pump flow rate will be 100-400 mL/min, and the flow rate will be recorded. Possible shock reversal will be assessed by the physician attending. Adsorber cartridges will be changed in every 12 hours. End of the study period (Te): 12 hours after shock reversal, death of the patient, or maximum of five days, whichever happens first.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours
Description: The standard medical therapy and method of Cytosorb treatment as detailed above will be applied. Adsorber cartridges will be changed in every 24 hours.
Study: NCT05664828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SN132D
Description: Manganese-based macromolecular MRI contrast agent
Study: NCT05129722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose combination polydiuretic therapy
Description: Low dose combination polydiuretic therapy treatment consists of:~Loop diuretic bumetanide 0.5 mg Mineralocorticoid receptor antagonist eplerenone 25 mg Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator monotherapy empagliflozin
Description: Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg
Study: NCT05142046

Intervention type: DRUG
Intervention: Fluid balance
Description: The intervention consists of classic and standardized anesthesia management of children undergoing cardiac surgery. All the data links to the fluid management will be extracted from the patient's chart in the intraoperative period as well as complications during the hospitalization in the postoperative period.
Study: NCT04268706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD30.CAR-T
Description: Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days
Study: NCT06410794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality with Beat Saber
Description: The VR activity used in the intervention was an add-on activity that did not replace any other activities in the programme. The off-the-shelf product Beat Saber (Beat Games, Prague, The Czech Republic) is the VR game of choice in our study. In collaboration with the participating clinics a systematic VR activity plan will be developed. This includes the selection of games and designing a plan that is interesting and motivating both for patients and clinicians.
Study: NCT06334783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tumor-infiltrating lymphocyte cells
Description: On day 0, all patients will receive autologous tumor-infiltrating lymphocyte cells administered.
Study: NCT05830240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type 1 (R130)
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study: NCT06306911

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia Melanocarpa extract
Description: Aronia Melanocarpa extract (AME) consisting of a mixture of anthocyanins and other polyphenols